All In Biotech

Drug Trial Radar · NCT04208698

A Scintigraphy Study in Adults With Diabetic Gastroparesis

A Randomized, Double-Blind Placebo-Controlled Scintigraphy Study to Investigate the Effect of CIN-102 on Gastric Emptying and Antral Contractility in Adults With Diabetic Gastroparesis

Last checked: Nov 19, 2026Latest source record: Aug 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

2

Actual

Start

Feb 17, 2020

Primary completion

Mar 31, 2020

Study completion Mar 31, 2020

Sponsor

Lead sponsor
CinDome Pharma, Inc.Industry
Sponsor type
Industry
First posted
Dec 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.

Conditions

  • Diabetic Gastroparesis

Interventions

  • CIN-102 Dose 1Drug

    Deuterated domperidone (deudomperidone)

  • CIN-102 Dose 2Drug

    Deuterated domperidone (deudomperidone)

  • Placebo for CIN-102Drug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.Time frame: Baseline to Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    El Paso, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.